FDA Limits Use of Johnson & Johnson COVID-19 Vaccine

May 06, 2022

The Food and Drug Administration on Thursday limited the use of the Johnson & Johnson (Janssen) COVID-19 vaccine to adults for whom other authorized or approved COVID-19 vaccines are not accessible or clinically appropriate. The agency limited use of the vaccine in response to an investigation of reported cases of thrombosis with thrombocytopenia syndrome (TTS), a syndrome of rare and potentially life-threatening blood clots. An updated fact sheet for health care providers administering the vaccine now reflects the revision of the authorized use of the vaccine and includes a warning statement that summarizes information on TTS risk.